Liquidia's Lung Drug Is Printing Money — But at a P/E Above 400, Can the Rally Last?

Shares of Liquidia Corporation surged 11.4% to $62.03 on June 4, extending a blistering post-earnings rally that has made it the top-performing healthcare stock over the past month. LQDA posted a one-month gain of 66.11% as of late May , driven by a blowout first quarter that has forced Wall Street to rethink its models. For shareholders riding the wave, the question is whether the business can grow into a stock price that now far exceeds every published analyst target.

A Quarter That Blew Away Every Estimate

Liquidia posted Q1 earnings of $0.52 per share, crushing the consensus estimate of $0.37, while revenue of $132.86 million beat the $116.62 million forecast.

That translates to a 40.5% EPS surprise and a 13.9% revenue beat.

Adjusted EBITDA — essentially cash profits from operations — hit $71.2 million, and this was the company's third consecutive profitable quarter. For a company that was burning cash just a year ago, that shift matters enormously.

One Drug Is Doing All the Heavy Lifting

Liquidia's inhaled lung-disease therapy drove a 44% sequential jump in sales and captured 23% of the inhaled prostacyclin market — up from just 10% two quarters earlier.

More than 4,500 prescriptions have been written, with roughly 3,750 patients started on the drug.

Management says it has a "clear line of sight" to $1 billion in annual revenue by 2027. That trajectory underpins the bullish case.

Analysts Are Playing Catch-Up — And Insiders Are Cashing Out

Post-earnings, H.C. Wainwright raised its price target to $67, Wells Fargo lifted to $62, and Jefferies moved to $60. Yet at $62.03, the stock already trades above most of those targets. The price-to-earnings ratio sits at a staggering 442 — meaning investors are paying $442 for every dollar of current annual profit — a level that demands near-flawless execution. Meanwhile, insiders have sold roughly $67.5 million in shares over the past three months , a pace that contrasts sharply with the stock's euphoric momentum.

The Pipeline Has to Deliver to Justify the Price

Liquidia is recruiting for a late-stage trial of a next-generation twice-daily therapy and expanding into lung scarring diseases and other rare conditions. Success would widen the revenue base beyond a single product. Failure would leave a stock priced for perfection dangerously exposed.